Difference between revisions of "Semuloparin (AVE-5026)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm")
m
 
(12 intermediate revisions by 2 users not shown)
Line 1: Line 1:
−
'''In clinical trials.'''
 
−
 
 
==General information==
 
==General information==
−
Class/mechanism: Hemisynthetic ultra low molecular weight heparin (ULMWH), binds to antithrombin III, accelerating its activity and inhibiting factor Xa, factor IIa, and thrombin.<ref>[https://www.sanofioncology.com/pipeline/semuloparin.aspx Semuloparin (AVE5026) manufacturer's website]</ref><ref name="SAVE-ONCO"> Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012 Feb 16;366(7):601-9. [http://www.nejm.org/doi/full/10.1056/NEJMoa1108898 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22335737 PubMed]</ref>
+
Class/mechanism: Hemisynthetic ultra low molecular weight heparin (ULMWH), binds to antithrombin III, accelerating its activity and inhibiting factor Xa, factor IIa, and thrombin.<ref name="SAVE-ONCO"> Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012 Feb 16;366(7):601-9. [https://doi.org/10.1056/NEJMoa1108898 link to original article] [https://pubmed.ncbi.nlm.nih.gov/22335737/ PubMed]</ref>
  
 
Route: SC
 
Route: SC
 
<br>Extravasation: n/a
 
<br>Extravasation: n/a
−
 
−
==Clinical trials==
 
−
*[http://clinicaltrials.gov/ct2/show/NCT00694382 Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy (SAVE-ONCO)]<ref name="SAVE-ONCO"></ref>
 
−
*[http://clinicaltrials.gov/ct2/show/NCT00709904 Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery (SAVE-HIP3)]
 
−
*[http://clinicaltrials.gov/ct2/show/NCT01567904 Study of AVE5026 at Weight-adjusted Doses in Children With a Central Venous Line]
 
−
*[http://clinicaltrials.gov/ct2/show/NCT00721760 Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery (SAVE-HIP2)]
 
−
*[http://clinicaltrials.gov/ct2/show/NCT00679588 Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery (SAVE-ABDO)]
 
−
*[http://clinicaltrials.gov/ct2/show/NCT00718224 Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery (SAVE-KNEE)]
 
−
*[http://clinicaltrials.gov/ct2/show/NCT00697099 Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery (SAVE-HIP1)]
 
−
*[http://clinicaltrials.gov/ct2/show/NCT00714597 Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility (SAVE-VEMED)]
 
−
*[http://clinicaltrials.gov/ct2/show/NCT00331838 Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery (TREK)]
 
  
 
==Patient drug information==
 
==Patient drug information==
 
No information available.
 
No information available.
 +
 +
==Also known as==
 +
*'''Code name:''' AVE-5026
  
 
==References==
 
==References==
 
<references/>
 
<references/>
 +
 +
[[Category:Drugs]]
 +
[[Category:Hematology medications]]
 +
[[Category:Subcutaneous medications]]
 +
 +
[[Category:Anticoagulants]]
 +
[[Category:Heparins]]
 +
[[Category:Ultralow molecular weight heparins]]
 +
 +
[[Category:Investigational drugs]]

Latest revision as of 23:14, 2 September 2023

General information

Class/mechanism: Hemisynthetic ultra low molecular weight heparin (ULMWH), binds to antithrombin III, accelerating its activity and inhibiting factor Xa, factor IIa, and thrombin.[1]

Route: SC
Extravasation: n/a

Patient drug information

No information available.

Also known as

  • Code name: AVE-5026

References

  1. ↑ Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012 Feb 16;366(7):601-9. link to original article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Semuloparin_(AVE-5026)&oldid=77086"